What the FDA labels say about taking them together
Metoclopramide and posaconazole
Metoclopramide's FDA label of May 18, 2026 names posaconazole in its drug interactions section, and posaconazole's label names metoclopramide too. The posaconazole label: “Interaction Drug: Fosamprenavir, metoclopramide*; Interaction: Monitor for breakthrough fungal infections ()”
Check it at the source: the metoclopramide FDA label on DailyMed (effective May 18, 2026, ANI Pharmaceuticals, Inc.); the posaconazole FDA label on DailyMed (effective August 3, 2026, Aurobindo Pharma Limited).
What does the metoclopramide label say about posaconazole?
Metoclopramide label, drug interactionsDrugs with Absorption Altered due to Increased Gastrointestinal Motility Clinical Impact The effect of metoclopramide on other drugs is variable. Increased gastrointestinal (GI) motility by metoclopramide may impact absorption of other drugs leading to decreased or increased drug exposure. Intervention Drugs with Decreased Absorption (e.g., digoxin, atovaquone, posaconazole oral suspension*, fosfomycin): Monitor for reduced therapeutic effect of the interacting drug. For digoxin monitor therapeutic drug concentrations and increase the digoxin dose as needed (see prescribing information for digoxin). …
Gimoti label (Evoke Pharma, Inc., February 20, 2026), drug interactionsIntervention; Drugs with Decreased Absorption (e.g., digoxin, atovaquone, posaconazole oral suspension Interaction does not apply to posaconazole delayed-release tablet., fosfomycin): Monitor for reduced therapeutic effect of the interacting drug. For digoxin, monitor therapeutic drug concentrations and increase the digoxin dose as needed (see prescribing information for digoxin). Drugs with Increased Absorption (e.g., sirolimus, tacrolimus, cyclosporine): Monitor therapeutic drug concentrations and adjust the dose as needed. See prescribing information for the interacting drug.
Source: FDA drug label (Gimoti, NDA209388), Evoke Pharma, Inc., effective February 20, 2026 (SPL set 95269b1f-779c-4ca0-9f86-e74e677f9900), via openFDA
Source: FDA drug label (Metoclopramide), NDA017854 (Ani Pharms), as published by ANI Pharmaceuticals, Inc., effective May 18, 2026 (SPL set 797aad80-0597-42f8-99d5-39de180c3b5a), via openFDA; the full label on DailyMed
What does the posaconazole label say about metoclopramide?
Posaconazole label, drug interactionsInteraction Drug: Fosamprenavir, metoclopramide*; Interaction: Monitor for breakthrough fungal infections ()
Noxafil label (Merck Sharp & Dohme LLC, February 13, 2026), drug interactionsInteraction Drug: Rifabutin, phenytoin, efavirenz, cimetidine, esomeprazole The drug interactions with esomeprazole and metoclopramide do not apply to Noxafil tablets or Noxafil PowderMix (,).; Interaction: Avoid coadministration unless the benefit outweighs the risks (,)
Source: FDA drug label (Noxafil, NDA022003), Merck Sharp & Dohme LLC, effective February 13, 2026 (SPL set b073b082-7b57-4423-8c06-4fd4263d6f84), via openFDA
Source: FDA drug label (POSACONAZOLE), Aurobindo Pharma Limited, effective August 3, 2026 (SPL set f8a26673-261c-4e8e-b1e1-9e23aaf7f285), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Metoclopramide | Posaconazole | |
|---|---|---|
| Labeled for | Acid reflux and ulcers, Nausea and vomiting | Fungal infections |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0439 per tablet 10 mg tablet | $2.03 per tablet 100 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once